WilliamSethAronsteinMD

Internal Medicine • Cincinnati, OH

Senior Medical Director

Join to view full profile

Dr. Aronstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aronstein's full profile

Already have an account?

Office
820 Ivy Ave
Cincinnati, OH 45246
Phone+1 513-772-9228

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1989
Johns Hopkins University School of MedicineClass of 1986

Certifications & Licensure

GA State Medical License 1997 - 2025
OH State Medical License 1999 - 2025
MD State Medical License 1988 - 1998
American Board of Internal Medicine Internal Medicine

Clinical Trials

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis. Start of enrollment: 2005 Oct 01
Terminated
Phase 1
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects Start of enrollment: 2008 Jan 01
Completed
Phase 1
Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers Start of enrollment: 2007 Mar 01
Completed
Phase 1
Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate Start of enrollment: 2007 Nov 01
Completed
Phase 1
Fecal Biomarker Study for Patients With Ulcerative Colitis Start of enrollment: 2007 Aug 01
Completed
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) Start of enrollment: 2016 Jul 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

43 citations
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Zelalem Temesgen, Charles D. Burger, Jason Baker, Christopher Polk, Claudia R. Libertin
The Lancet. Respiratory Medicine. 2021-12-01
145 citations
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthr...
Piotr Krzeski, Chris Buckland-Wright, Géza Bálint, Gary A Cline, Karen J Stoner
Arthritis Research & Therapy. 2007-10-24
66 citations
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: t...
Patrick Garnero, William S. Aronstein, Stanley Cohen, Philip G. Conaghan, Gary A Cline
Osteoarthritis and Cartilage. 2008-06-01